Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 780 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Gene expression study Clear all
Completed No phase listed Observational

Mechanisms of Ischemic Stroke in Cancer Patients

NCT02604667
View directory record Official record
Conditions
Stroke, Cancer
Interventions
Blood tests, Transcranial Doppler Microemboli Detection Study
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 23, 2026, 9:15 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of Botulinum Toxin on Oral Aperture in Patients With Scleroderma

NCT04523506
View directory record Official record
Conditions
Scleroderma
Interventions
Botulinum toxin(Botox)
Biological
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 23, 2026, 9:15 AM EDT
Active, not recruiting Phase 3 Interventional

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT05445778
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
74
States / cities
Mobile, Alabama • Phoenix, Arizona • Irvine, California + 62 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 23, 2026, 9:15 AM EDT
Completed Phase 1 Interventional

Biodistribution and Dosimetry of Serial PET Imaging With Ga-68 Labeled F(ab') 2- Trastuzumab

NCT00613847
View directory record Official record
Conditions
Solid Tumors
Interventions
PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Oct 23, 2026, 9:15 AM EDT
Active, not recruiting Not applicable Interventional Results available

MRI-Based Preoperative Accelerated Partial Breast Irradiation

NCT02728076
View directory record Official record
Conditions
Breast Cancer
Interventions
Phase II - Preoperative Radiation followed by Lumpectomy.
Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
40 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma

NCT00114738
View directory record Official record
Conditions
Lymphoma, Mantle Cell, Mantle Cell Lymphoma
Interventions
Rituximab (R), EPOCH, Bortezomib (B), Bortezomib, Bortezomib or observation
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 23, 2026, 9:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

NCT04270591
View directory record Official record
Conditions
C-Met Exon 14 Mutation
Interventions
Glumetinib
Drug
Lead sponsor
Haihe Biopharma Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 23, 2026, 9:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression

NCT02325739
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC), Solid Malignancies
Interventions
FGF401, PDR001
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 23, 2026, 9:15 AM EDT
Active, not recruiting No phase listed Observational

MElanoma Research Lymph Node Prediction Implementation National_001

NCT04759781
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
SkylineDx
Industry
Eligibility
18 Years and older
Enrollment
1,820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
9
States / cities
Tampa, Florida • Atlanta, Georgia • Lexington, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 23, 2026, 9:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CARESS: An Investigation of Effects of CARESS

NCT03758027
View directory record Official record
Conditions
Craving, Self Efficacy, Affective; Reaction, Substance Abuse
Interventions
CARESS, Isometric Exercise
Behavioral
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 23, 2026, 9:15 AM EDT
Recruiting Phase 2 Interventional

Enhanced Pain Coping in Cancer (EPIC): A Study of Managing Treatment-Related Joint Pain in Breast Cancer Survivors

NCT06728579
View directory record Official record
Conditions
Breast Cancer Survivor
Interventions
Mindfulness Oriented Recovery Enhancement (MORE), Questionnaires, Supportive Psychotherapy (SG)
Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
San Diego, California • Tallahassee, Florida • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 23, 2026, 9:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia

NCT00691769
View directory record Official record
Conditions
Central Centrifugal Scarring Alopecia, Lichen Planopilaris, Discoid Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Wake Forest University
Other
Eligibility
30 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 23, 2026, 9:15 AM EDT
Withdrawn Not applicable Interventional

Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma

NCT00513188
View directory record Official record
Conditions
Lymphoma
Interventions
denileukin diftitox, cyclophosphamide, cytarabine, doxorubicin hydrochloride, leucovorin calcium, methotrexate, prednisone, vincristine sulfate, protein expression analysis, flow cytometry, laboratory biomarker analysis
Biological · Drug · Genetic + 1 more
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 23, 2026, 9:15 AM EDT
Terminated No phase listed Observational

Studies of Biological Changes Related to Weight Loss After Gastric Bypass Surgery

NCT00120562
View directory record Official record
Conditions
Obesity, Morbid Obesity, Weight Loss
Interventions
Gastric Bypass Surgery
Procedure
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2009 · Synced Oct 23, 2026, 9:15 AM EDT
Recruiting Not applicable Interventional

A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery

NCT06127979
View directory record Official record
Conditions
Breast Cancer
Interventions
blood draw
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 9:15 AM EDT
Recruiting Phase 2 Interventional

Tirzepatide for Treatment of CCCA

NCT07734870
View directory record Official record
Conditions
Central Centrifugal Cicatricial Alopecia (CCCA)
Interventions
Tirzepatide
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 23, 2026, 9:15 AM EDT
Completed No phase listed Observational

SynapDx Autism Gene Expression Analysis Study (STORY)

NCT01810341
View directory record Official record
Conditions
Autism
Interventions
Not listed
Lead sponsor
SynapDx
Industry
Eligibility
18 Months to 60 Months
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
18
States / cities
Scottsdale, Arizona • Long Beach, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 23, 2026, 9:15 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

NCT04471727
View directory record Official record
Conditions
Small-Cell Lung Cancer, Neuroendocrine Carcinoma
Interventions
Gocatamig, Atezolizumab, Ifinatamab Deruxtecan (I-DXd)
Biological
Lead sponsor
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 23, 2026, 9:15 AM EDT
Recruiting Phase 2 Interventional

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

NCT04614103
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
LN-145
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
27
States / cities
Gilbert, Arizona • Miami, Florida • Tampa, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 23, 2026, 9:15 AM EDT
Recruiting Phase 1 Interventional

Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma

NCT07748988
View directory record Official record
Conditions
Refractory Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
Interventions
casdatifan
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 100 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 9:15 AM EDT
Completed No phase listed Observational

Effects of Epidermal Growth Factor Receptor Inhibitor Therapy in the Skin of Cancer Patients

NCT00483457
View directory record Official record
Conditions
Solid Tumor
Interventions
enzyme inhibitor therapy, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 23, 2026, 9:15 AM EDT
Completed Phase 1 Interventional

Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors

NCT00423865
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cisplatin, everolimus, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Oct 23, 2026, 9:15 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Outcomes AlloMap Registry: the Long-term Management and Outcomes of Heart Transplant Recipients With AlloMap Testing

NCT01833195
View directory record Official record
Conditions
Cardiac Transplant Failure, Cardiac Transplant Rejection, Heart Diseases
Interventions
Not listed
Lead sponsor
CareDx
Industry
Eligibility
15 Years and older
Enrollment
2,444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
36
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 23, 2026, 9:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

NCT01165996
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Myelodysplastic Syndromes, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Thrombocytopenia
Interventions
flow cytometry, DNA methylation analysis, cytogenetic analysis, decitabine, microarray analysis, gene expression analysis, pharmacological study, polymorphism analysis
Other · Drug · Genetic
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 23, 2026, 9:15 AM EDT